Study Results from Genentech Inc. Update Understanding of Biotechnology (A Comparative Clinical Pharmacology Analysis of Fda-approved Targeted Covalent Inhibitors Vs. Reversible Inhibitors In Oncology).
| Předmět: | |
|---|---|
| Zdroj: | Medical Letter on the CDC & FDA; 8/30/2024, p1495-1495, 1p |
| Abstrakt: | The article examines a comparative clinical pharmacology analysis of U.S. Food and Drug Administration (FDA)-approved targeted covalent inhibitors (TCIs) versus reversible inhibitors (RIs) in oncology. Topics discussed include the pharmacokinetics and efficacy of TCIs, their therapeutic benefits and risks compared to RIs, and their impact on drug-drug interactions. |
| Databáze: | Complementary Index |
| Externí odkaz: |
|